Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475112 | 0.88 | CHRNA7 (0.37) | KDM1A | |
| SCHEMBL4463819 | 0.88 | HSD11B1 (0.38) | HSD11B1 | |
| Bromide SCHEMBL4466117 | 0.86 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL4463770 | 0.86 | ALOX5AP (0.34) | — | |
| SCHEMBL4463735 | 0.85 | RXFP1 (0.39) | SLC6A4KDM4EALDH1A1FYN | |
| SCHEMBL5220760 | 0.82 | CYP11B1 (0.36) | CYP3A4CYP2D6ALDH1A1FYN | |
| SCHEMBL4461401 | 0.82 | ALOX5AP (0.31) | KDM1A | |
| Bromide SCHEMBL4479130 | 0.81 | CYP11B1 (0.35) | CYP3A4CYP2D6ALDH1A1FYN | |
| SCHEMBL1483198 | 0.81 | ALOX5AP (0.37) | AKT1AKT2AKT3 | |
| SCHEMBL1482889 | 0.81 | ALOX5AP (0.38) | KDM1AFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | claimed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | PAICS, CYC1, AADAC | SLC6A2 2250/4885SLC6A4 2872/4885SLC6A3 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.